Advance Research Associates Joins DATATRAK International, Inc.'s CRO Connect Program(TM)
Published: Jul 20, 2009
"We look forward to a long and successful partnership with DATATRAK, delivering the highest quality of services and solutions to our clients," stated Peter Shabe, CEO of Advance Research Associates.
"We welcome ARA to a growing list of new CRO Connect partners," said Laurence Birch, DATATRAK's CEO. "ARA is known for it Data Management and Biostats expertise, two areas in which DATATRAK eClinical excels in adding value. We are excited to support our new partner as ARA expands its service offering."
DATATRAK's CRO Connect Program is a collaborative initiative with CROs that offers the benefits of our comprehensive DATATRAK eClinical(TM) solution through an innovative Enterprise Transfer program. This program allows CROs to package their services around our eClinical(TM) platform in order to gain efficiencies and increased market share. The CRO Connect Program's flexible pricing and specialized consulting and professional services provides participants with the tools necessary to realize new growth opportunities.
Founded in 1996, Advance Research Associates with more than 75 years of collective practical clinical research experience has become a trusted clinical research partner to the pharmaceutical, biotech, and medical device industries. In the years since its inception, ARA has provided a spectrum of innovative solutions and lent its expertise across a wide range of projects. While these customized solutions are always based entirely on client need, the success of any project hinges on the strength of the personal relationship developed between client and partner through daily communication. ARA's collaborative management philosophy supports extensive interaction, resulting in clients consistently achieving their highest objectives. For more information on ARA, visit www.araonline.net.
About DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
SOURCE DATATRAK International, Inc.